Illumina (ILMN) Preferred Stock Liabilities (2011)
Illumina's (ILMN) quarterly Preferred Stock Liabilities came in at $25.5 million in Q2 2011, down 67.42% quarter-over-quarter from $78.4 million in Q1 2011.
Powered by 
Analysis
Illumina (ILMN) Preferred Stock Liabilities (2011) Analysis & Trends
Illumina (ILMN) has reported Preferred Stock Liabilities for 1 consecutive years, with $25.5 million the latest figure, recorded in Q2 2011.
- For the quarter ending Q2 2011, Preferred Stock Liabilities changed N/A year-over-year to $25.5 million; the trailing twelve-month figure through Apr 2011 stood at $25.5 million (changed N/A YoY), and the FY2011 full-year result was $78.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities retreated to $25.5 million in Q2 2011 per ILMN's latest filing, from $78.4 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $78.4 million in Q1 2011 and bottomed at $25.5 million in Q2 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | - |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | - |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | - |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | - |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | - |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | - |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | - |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | - |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | - |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | - |